Literature DB >> 30021168

Aberrant Deactivation-Induced Gain of Function in TRPM4 Mutant Is Associated with Human Cardiac Conduction Block.

Wenying Xian1, Xin Hui1, Qinghai Tian1, Hongmei Wang2, Alessandra Moretti3, Karl-Ludwig Laugwitz3, Veit Flockerzi2, Sandra Ruppenthal1, Peter Lipp4.   

Abstract

A gain-of-function mutation in the Ca2+-activated transient receptor potential melastatin member 4 (TRPM4A432T) is linked to life-threatening cardiac conduction disturbance, but the underlying mechanism is unclear. For deeper insights, we used photolysis of caged Ca2+, quantitative Ca2+, and electrophysiological measurements. TRPM4A432T's 2-fold larger membrane current was associated with 50% decreased plasma membrane expression. Kinetic analysis unveiled 4-fold slower deactivation that was responsible for the augmented membrane current progressively rising during repetitive human cardiac action potentials. Rational mutagenesis of TRPM4 at position 432 revealed that the bulkiness of the amino acid was key to TRPM4A432T's aberrant gating. Charged amino acids rendered the channel non-functional. The slow deactivation caused by an amino acid substitution at position 432 from alanine to the bulkier threonine represents a key contributor to the gain of function in TRPM4A432T. Thus, our results add a mechanism in the etiology of TRP channel-linked human cardiac channelopathies.
Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  TRPM4; calcium; cardiac arrhythmia; disease mechanism; flash photolysis; inherited human disease; membrane current; molecular modeling; mutation; patch clamp

Mesh:

Substances:

Year:  2018        PMID: 30021168     DOI: 10.1016/j.celrep.2018.06.034

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  5 in total

1.  Propagation Failure by TRPM4 Overexpression.

Authors:  Namit Gaur; Thomas Hof; Michel Haissaguerre; Edward J Vigmond
Journal:  Biophys J       Date:  2018-12-07       Impact factor: 4.033

Review 2.  TRPM4 in Cancer-A New Potential Drug Target.

Authors:  Anna Borgström; Christine Peinelt; Paulina Stokłosa
Journal:  Biomolecules       Date:  2021-02-05

3.  The novel TRPM4 c.448G>T variant is associated with familial conduction disorders, cardiomyopathy, and sudden cardiac death.

Authors:  Boldizsar Kovacs; Stephan Winnik; Argelia Medeiros-Domingo; Sarah Costa; Guan Fu; Saskia Biskup; Frank Ruschitzka; Andreas J Flammer; Felix C Tanner; Firat Duru; Ardan M Saguner
Journal:  Cardiol J       Date:  2021-12-13       Impact factor: 3.487

4.  In Vitro Drug Screening Using iPSC-Derived Cardiomyocytes of a Long QT-Syndrome Patient Carrying KCNQ1 & TRPM4 Dual Mutation: An Experimental Personalized Treatment.

Authors:  Feifei Wang; Yafan Han; Wanyue Sang; Lu Wang; Xiaoyan Liang; Liang Wang; Qiang Xing; Yankai Guo; Jianghua Zhang; Ling Zhang; Tuerhong Zukela; Jiasuoer Xiaokereti; Yanmei Lu; Xianhui Zhou; Baopeng Tang; Yaodong Li
Journal:  Cells       Date:  2022-08-11       Impact factor: 7.666

Review 5.  Transient receptor potential channels in cardiac health and disease.

Authors:  Thomas Hof; Sébastien Chaigne; Alice Récalde; Laurent Sallé; Fabien Brette; Romain Guinamard
Journal:  Nat Rev Cardiol       Date:  2019-06       Impact factor: 32.419

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.